$ANIX
Anixa Biosciences Inc Stock $anix

$anix Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 10-Q Financial Statement

#000149315223007994 Filed on March 17, 2023

Income Statement

Concept	2023 Q1	2022 Q1
Revenue		$0.00
YoY Change		-100.0%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$1.488M	$2.042M
YoY Change	-27.13%	33.46%
% of Gross Profit
Research & Development	$1.068M	$1.838M
YoY Change	-41.89%	121.45%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$1.068M	$3.880M
YoY Change	-72.47%	64.41%
Operating Profit	-$2.556M	-$3.880M
YoY Change	-34.12%
Interest Expense	$202.0K	$1.000K
YoY Change	20100.0%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income	-$2.354M	-$3.879M
YoY Change	-39.31%	73.95%
Income Tax
% Of Pretax Income
Net Earnings	-$2.322M	-$3.829M
YoY Change	-39.36%	73.26%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.08	-$0.13
Diluted Earnings Per Share	-$0.08	-$127.1K
COMMON SHARES
Basic Shares Outstanding	30.92M shares
Diluted Shares Outstanding	30.92K shares	30.13K shares

Balance Sheet

Concept	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$27.70M	$34.53M
YoY Change	-19.77%	147.0%
Cash & Equivalents	$9.790M	$29.78M
Short-Term Investments	$17.91M	$4.749M
Other Short-Term Assets	$256.0K	$464.0K
YoY Change	-44.83%	-20.0%
Inventory
Prepaid Expenses
Receivables	$147.0K
Other Receivables	$0.00
Total Short-Term Assets	$28.11M	$34.99M
YoY Change	-19.69%	140.34%
LONG-TERM ASSETS
Property, Plant & Equipment	$201.0K	$244.0K
YoY Change	-17.62%	510.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$201.0K	$244.0K
YoY Change	-17.62%	510.0%
TOTAL ASSETS
Total Short-Term Assets	$28.11M	$34.99M
Total Long-Term Assets	$201.0K	$244.0K
Total Assets	$28.31M	$35.24M
YoY Change	-19.67%	141.36%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$110.0K	$504.0K
YoY Change	-78.17%	-1.18%
Accrued Expenses	$1.075M	$1.283M
YoY Change	-16.21%	27.03%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.232M	$1.787M
YoY Change	-31.06%	16.8%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$162.0K	$209.0K
YoY Change	-22.49%
Total Long-Term Liabilities	$162.0K	$209.0K
YoY Change	-22.49%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.232M	$1.787M
Total Long-Term Liabilities	$162.0K	$209.0K
Total Liabilities	$1.394M	$1.275M
YoY Change	9.33%	27.5%
SHAREHOLDERS EQUITY
Retained Earnings	-$220.7M
YoY Change
Common Stock	$309.0K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$27.79M	$33.96M
YoY Change
Total Liabilities & Shareholders Equity	$28.31M	$35.24M
YoY Change	-19.67%	141.36%

Cashflow Statement

Concept	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$2.322M	-$3.829M
YoY Change	-39.36%	73.26%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$1.988M	-$1.197M
YoY Change	66.08%	2.31%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$585.0K	$1.850M
YoY Change	-131.62%	172.06%
Cash From Investing Activities	-$585.0K	$1.850M
YoY Change	-131.62%	172.06%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net		$0.00
YoY Change		-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$3.000K
YoY Change
NET CHANGE
Cash From Operating Activities	-$1.988M	-1.197M
Cash From Investing Activities	-$585.0K	1.850M
Cash From Financing Activities	$3.000K
Net Change In Cash	-$2.570M	$0.00
YoY Change		-100.0%
FREE CASH FLOW
Cash From Operating Activities	-$1.988M	-$1.197M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0000715446
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--10-31
CY2022Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised		usd
CY2022Q1	ANIX	Common Stock Issued To Consultants CommonStockIssuedToConsultants		usd
CY2022Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables		usd
CY2022Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-01-31
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	001-37492
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	ANIXA BIOSCIENCES, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	11-2622630
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	3150 Almaden Expressway
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 250
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	San Jose
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	95118
CY2023Q1	dei	City Area Code CityAreaCode	(408)
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	708-9808
CY2023Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $.01 per share
CY2023Q1	dei	Trading Symbol TradingSymbol	ANIX
CY2023Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	30924868	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	9790000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	12360000	usd
CY2023Q1	us-gaap	Short Term Investments ShortTermInvestments	17912000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	17327000	usd
CY2023Q1	us-gaap	Receivables Net Current ReceivablesNetCurrent	147000	usd
CY2022Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	47000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	256000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	466000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	28105000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	30200000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	201000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	212000	usd
CY2023Q1	us-gaap	Assets Assets	28306000	usd
CY2022Q4	us-gaap	Assets Assets	30412000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	110000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	265000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1075000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1726000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	47000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	46000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1232000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2037000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	162000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	175000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	1394000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	2212000	usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	100
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	100
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	19860	shares
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	19860	shares
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30922830	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30922830	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	30913902	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	30913902	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	309000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	309000	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	248189000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	247123000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-220707000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-218385000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	27791000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	29047000	usd
CY2023Q1	us-gaap	Minority Interest MinorityInterest	-879000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-847000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	26912000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	28200000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	28306000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	30412000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1068000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	188000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-155000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	368000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-651000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1838000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1488000	usd
CY2022Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2042000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	2556000	usd
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	3880000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2556000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-3880000	usd
CY2023Q1	us-gaap	Interest Income Other InterestIncomeOther	202000	usd
CY2022Q1	us-gaap	Interest Income Other InterestIncomeOther	1000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-2354000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-3879000	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-32000	usd
CY2022Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-50000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2322000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-3829000	usd
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.08
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.13
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30921	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	30125	shares
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	28200000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	957000	usd
CY2023Q1	ANIX	Adjustments To Additional Paid In Capital Stock Option And Warrants Issued Value AdjustmentsToAdditionalPaidInCapitalStockOptionAndWarrantsIssuedValue	81000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	25000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	3000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-2354000	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	26912000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	34767000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	34767000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	2135000	usd
CY2022Q1	ANIX	Adjustments To Additional Paid In Capital Stock Option And Warrants Issued Value AdjustmentsToAdditionalPaidInCapitalStockOptionAndWarrantsIssuedValue	219000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-3879000	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	33242000	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	33242000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-2354000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-3879000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	957000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2135000	usd
CY2023Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	81000	usd
CY2022Q1	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	219000	usd
CY2023Q1	ANIX	Common Stock Issued To Consultants CommonStockIssuedToConsultants	25000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	11000	usd
CY2022Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	10000	usd
CY2023Q1	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	100000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-210000	usd
CY2022Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	147000	usd
CY2023Q1	ANIX	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-12000	usd
CY2022Q1	ANIX	Increase Decrease In Operating Lease Liabilities IncreaseDecreaseInOperatingLeaseLiabilities	-9000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1988000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1197000	usd
CY2023Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	7835000	usd
CY2022Q1	us-gaap	Payments To Acquire Short Term Investments PaymentsToAcquireShortTermInvestments	3499000	usd
CY2023Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	7250000	usd
CY2022Q1	us-gaap	Proceeds From Sale Of Short Term Investments ProceedsFromSaleOfShortTermInvestments	5349000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-585000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	1850000	usd
CY2023Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	3000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2570000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	653000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	12360000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	29128000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	9790000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	29781000	usd
CY2023Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	100000000	shares
CY2022Q4	us-gaap	Minority Interest MinorityInterest	-847000	usd
CY2023Q1	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-32000	usd
CY2023Q1	us-gaap	Minority Interest MinorityInterest	-879000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber	300000	shares
CY2023Q1	ANIX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice	6.56
CY2023Q1	ANIX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableNumber	300000	shares
CY2023Q1	ANIX	Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercisableWeightedAverageExercisePrice	6.56
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding	0	usd
CY2023Q1	ANIX	Money Market Funds Cash And Cash Equivalents MoneyMarketFundsCashAndCashEquivalents	9594000	usd
CY2023Q1	ANIX	Certificates Of Deposit Short Term Investments CertificatesOfDepositShortTermInvestments	7450000	usd
CY2023Q1	ANIX	Us Treasury Bills Short Term Investment USTreasuryBillsShortTermInvestment	10462000	usd
CY2023Q1	ANIX	Financial Assets FinancialAssets	27506000	usd
CY2022Q4	ANIX	Money Market Funds Cash And Cash Equivalents MoneyMarketFundsCashAndCashEquivalents	11175000	usd
CY2022Q4	ANIX	Certificates Of Deposit Cash Equivalents CertificatesOfDepositCashEquivalents	1000000	usd
CY2022Q4	ANIX	Certificates Of Deposit Short Term Investments CertificatesOfDepositShortTermInvestments	13700000	usd
CY2022Q4	ANIX	Treasury Bills And Bonds Short Term Investments TreasuryBillsAndBondsShortTermInvestments	3627000	usd
CY2022Q4	ANIX	Financial Assets FinancialAssets	29502000	usd
CY2023Q1	us-gaap	Payments For Rent PaymentsForRent	17000	usd
CY2022Q1	us-gaap	Payments For Rent PaymentsForRent	17000	usd
CY2023Q1	ANIX	Revenue Percentage RevenuePercentage	1	pure
CY2023Q1	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued	0	usd
CY2023Q1	us-gaap	Accrued Payroll Taxes Current And Noncurrent AccruedPayrollTaxesCurrentAndNoncurrent	461000	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current And Noncurrent AccruedPayrollTaxesCurrentAndNoncurrent	1144000	usd
CY2023Q1	us-gaap	Accrued Royalties Current And Noncurrent AccruedRoyaltiesCurrentAndNoncurrent	577000	usd
CY2022Q4	us-gaap	Accrued Royalties Current And Noncurrent AccruedRoyaltiesCurrentAndNoncurrent	577000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	37000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	5000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	1075000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	1726000	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAccrued	0	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	49000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	67000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	70000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	65000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	251000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	42000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	209000	usd
CY2023Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	4	numbers
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-2354000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-3879000	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	-2354000	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	-3879000	usd
CY2023Q1	us-gaap	Costs And Expenses CostsAndExpenses	2556000	usd
CY2022Q1	us-gaap	Costs And Expenses CostsAndExpenses	3880000	usd
CY2023Q1	ANIX	Noncash Sharebased Compensation NoncashSharebasedCompensation	-1063000	usd
CY2022Q1	ANIX	Noncash Sharebased Compensation NoncashSharebasedCompensation	-2354000	usd
CY2023Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1493000	usd
CY2022Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1526000	usd
CY2023Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1493000	usd
CY2022Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1526000	usd
CY2023Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1493000	usd
CY2022Q1	us-gaap	Operating Costs And Expenses OperatingCostsAndExpenses	1526000	usd
CY2023Q1	us-gaap	Assets Assets	28306000	usd
CY2022Q4	us-gaap	Assets Assets	30412000	usd
CY2023Q1	us-gaap	Assets Assets	28306000	usd
CY2022Q4	us-gaap	Assets Assets	30412000	usd

Files In Submission

Name	View Source	Status
form10-q_htm.xml	Edgar Link	completed
0001493152-23-007994-index-headers.html	Edgar Link	pending
0001493152-23-007994-index.html	Edgar Link	pending
0001493152-23-007994.txt	Edgar Link	pending
0001493152-23-007994-xbrl.zip	Edgar Link	pending
anix-20230131.xsd	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
anix-20230131_cal.xml	Edgar Link	unprocessable
anix-20230131_def.xml	Edgar Link	unprocessable
anix-20230131_lab.xml	Edgar Link	unprocessable
anix-20230131_pre.xml	Edgar Link	unprocessable
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ANIX
Anixa Biosciences Inc Stock $anix

2023 Q1 Form 10-Q Financial Statement

#000149315223007994 Filed on March 17, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ANIX Anixa Biosciences Inc Stock $anix

2023 Q1 Form 10-Q Financial Statement

#000149315223007994 Filed on March 17, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ANIX
Anixa Biosciences Inc Stock $anix